[Applause] You failed. Two words we all know too well. Failure can echo in our minds, overshadowing every victory, every compliment, and every moment of joy.In a world that often celebrates success, failure makes us question our worth. But what if we viewed failure differently. What if we saw it as as an essential part of growth, a stepping stone rather than a stumbling block.Today I want to share how those two words, you failed, became the catalyst for hope and transformation in my life. How I discovered t ...

There are moments which mark your life. Moments when you realize nothing will ever be the same. And time is divided into two parts.Before this and after this. Sometimes you can feel such a moment coming. And that's the test.Or so I tell myself. I tell myself that at times like that, strong people keep moving forward anyway, no matter what they're going to find. Hi, I've been told that there's a handful of you here who were told that I was going to be giving a speech about the most expensive haircut I ever r ...

Economic Overview - Inflation is cooling at a faster rate than expected, with the consumer price index (CPI) rising only 0.1% sequentially in May, lower than the consensus estimate of 0.2% [3][9] - Year-over-year, CPI increased 2.4%, aligning with analysts' expectations, while core CPI rose 0.1% sequentially and 2.8% year-over-year, both lower than expected [3][4] Consumer Discretionary Stocks - Positive sentiment in the market suggests investing in consumer discretionary stocks such as Carnival Corporation & plc (CCL), Fox Corporation (FOX), Netflix, Inc. (NFLX), and Interface, Inc. (TILE) [2][8] - These stocks have seen positive earnings estimate revisions in the last 60 days, with each carrying a Zacks Rank 2 (Buy) [2] Company-Specific Insights Carnival Corporation & plc - Carnival Corporation operates as the largest cruise operator globally, carrying nearly half of the global cruise guests [10] - The expected earnings growth rate for the current year is 31.7%, with the Zacks Consensus Estimate for current-year earnings improving by 1.1% over the last 60 days [10] Fox Corporation - Fox Corporation produces and distributes news, sports, and entertainment content, with brands including FOX News and FOX Sports [11] - The expected earnings growth rate for the current year is 32.4%, with the Zacks Consensus Estimate for current-year earnings improving by 1.1% over the past 60 days [11] Netflix, Inc. - Netflix is a pioneer in the streaming space, aggressively building its portfolio of original shows to maintain its leading position [12] - The expected earnings growth rate for the current year is 27.7%, with the Zacks Consensus Estimate for current-year earnings improving by 3.3% over the past 60 days [12] Interface, Inc. - Interface is the world's largest manufacturer of modular carpets, committed to sustainability while enhancing shareholder value [13] - The expected earnings growth rate for the current year is 8.2%, with the Zacks Consensus Estimate for current-year earnings improving by 2.6% over the past 60 days [13]

[Music] So, I'm an anthropologist. Uh, which means I uh uh spend a lot of time asking what it means to be human. Not just in a tidy academic sense, but in all its gritty, glorious contradictions.from how we've evolved to be this flawed physical species to how this physical species has moved and migrated to nearly every square inch of the earth and not just survived in those different places but thrived. Not because we've done the same thing in all those different places but because we've done things differe ...

Monogram Technologies (MGRM) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants Noel Knape - Chief Financial OfficerBenjamin Sexson - CEONone - Executive Conference Call Participants Thomas Kerr - Senior AnalystJason Wittes - Managing Director & Senior Research Analyst Operator Good afternoon, everyone, and welcome to the Monogram Technologies first quarter twenty twenty five financial results and business update conference call. A question and answer session will follow the formal presenta ...

Financial Data and Key Metrics Changes - For Q1 2025, the company reported cash of $13.3 million, with an operating cash flow of $2.3 million, resulting in a monthly cash burn of approximately $800,000, down from $1.1 to $1.2 million last year [5][6] - The company forecasts a monthly cash burn of about $1 million for the remainder of the year, indicating a strong balance sheet with over a year of cash available [6] Business Line Data and Key Metrics Changes - The company is in the final stages of the verification and validation phase of its robotic system development, which has allowed for a reduction in variable costs [5] - The company has 27 full-time employees focused on ongoing R&D to achieve set milestones [5] Market Data and Key Metrics Changes - The orthopedic surgery market is highly consolidated, with Stryker holding a significant market share of approximately 70% with its Mako robot [15][16] - The company aims to capitalize on the generational shift in orthopedic surgery, as many new surgeons are being trained on robotic systems, which could lead to a significant market opportunity [17] Company Strategy and Development Direction - The company received FDA clearance for its embossed total TKA system, marking a significant milestone in its history [8][10] - The company plans to conduct a pilot placement with a major institution in the U.S. to demonstrate the system's value proposition and clinical performance [10] - The company is also preparing for a multicenter clinical trial in India, which will be the first clinical investigation involving autonomous robotic total knee surgeries on live patients [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential impact of robotic precision and efficiency in orthopedic surgeries [13][19] - The company believes it is at the forefront of a paradigm shift in orthopedic surgery, with plans to demonstrate its capabilities in live patient cases [14][19] Other Important Information - The company is actively showcasing its system with key opinion leaders and preparing for additional placements, emphasizing a slow and methodical rollout to ensure high service levels [11] - The company is exploring capital opportunities to accelerate growth, indicating a need for additional capital to support commercialization efforts [62] Q&A Session Summary Question: Can you provide more detail on timelines for the U.S. and India regarding technical and regulatory hurdles? - The company expects to perform live patient surgeries in India within 90 business days and anticipates the first placement in the U.S. to occur in Q2 or early Q3 [25][26] Question: What differentiators will allow Monogram to compete with Stryker? - The company aims to focus on accuracy, safety, and minimal surgeon fatigue, with plans to leverage AI for landmark identification and improve tensioning efficiency [31][33][39] Question: Can you provide more color on system enhancements? - Significant enhancements have been made to the feed rate and software of the robot, with ongoing internal testing to ensure safety and performance [50][51] Question: Is the domestic launch considered a trial or full commercial launch? - The launch is termed a pilot launch, allowing for real-world evaluation and surgeon training before broader commercialization [53][55] Question: What are the capital needs in light of upcoming clinical trials? - The company is actively exploring capital opportunities to accelerate growth, with strong interest from investors [62][63]

OrthoPediatrics (KIDS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Company Participants Philip Taylor - PrincipalDavid Bailey - President, CEO & DirectorFred Hite - CFO & COORick Wise - Managing Director - Medical Technology & SuppliesBen Haynor - Managing DirectorJoseph Conway - Equity Research Associate Conference Call Participants Matt O'Brien - AnalystRyan Zimmerman - Managing Director & Medical Technology Analyst Operator Good day and thank you for standing by. Welcome to the OrthoPediatrics Corpora ...

OrthoPediatrics (KIDS) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 Good day and thank you for standing by. Welcome to the OrthoPediatrics Corporation First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during this session, you will need to press 11 on your telephone. You will then hear automated message advising your hand is raised. To wi ...

Core Insights - OrthoPediatrics Corp. reported a 17% year-over-year increase in total revenue for Q1 2025, reaching $52.4 million compared to $44.7 million in Q1 2024 [4] - The company continues to focus on pediatric orthopedics, achieving significant growth in both U.S. and international markets [3][4] Financial Performance - Total revenue for Q1 2025 was $52.4 million, a 17% increase from $44.7 million in Q1 2024 [4] - U.S. revenue increased by 19% to $40.9 million, representing 78% of total revenue, while international revenue grew by 11% to $11.5 million, accounting for 22% of total revenue [4] - Trauma and Deformity revenue rose 14% to $37.9 million, and Scoliosis revenue surged 34% to $13.7 million [5][4] - Gross profit for Q1 2025 was $38.3 million, a 19% increase from $32.2 million in the same period last year, with a gross profit margin of 73% [6] Operating Expenses - Total operating expenses for Q1 2025 were $49.2 million, an 18% increase from $41.9 million in Q1 2024, primarily due to increased personnel and non-cash stock compensation [7][10] - Sales and marketing expenses rose by 17% to $16.6 million, driven by higher sales commissions [8] Profitability Metrics - The net loss for Q1 2025 was $10.7 million, compared to a net loss of $7.8 million in Q1 2024, with a net loss per share of $0.46 [11] - Adjusted EBITDA for Q1 2025 was a loss of $0.4 million, an improvement from a loss of $1.1 million in Q1 2024 [11][29] Cash Flow and Guidance - The company reduced free cash flow usage by 35% compared to the same period last year and anticipates achieving positive free cash flow in Q4 2025 [8] - Full-year 2025 revenue guidance was increased to between $236.0 million and $242.0 million, reflecting a growth of 15% to 18% compared to 2024 [13]

Core Insights - OrthoPediatrics Corp. has announced the expansion of its Trauma and Deformity portfolio with the introduction of the 3P Pediatric Plating Platform Hip System, marking its fifth FDA approval in 2025 [1][3]. Product Development - The 3P Pediatric Plating Platform Hip System is designed to modernize trauma and deformity correction treatments in lower extremities, providing surgeons with enhanced coverage for various indications through unique implants and instruments [2]. - The beta launch of the 3P Hip is expected to be followed by the 3P Small/Mini system in early 2026, with additional systems planned for future launches, aiming to transform the company's plate and screw product portfolio [2]. Company Strategy - The Trauma and Deformity division President highlighted the 3P Pediatric Plating Platform as a significant opportunity to address unmet needs in the market, representing one of the largest product initiatives in the company's history [3]. - The CEO emphasized the commitment to providing a comprehensive portfolio of innovative orthopedic treatments for pediatric patients, reflecting the company's focus on expanding its product offerings [3]. Company Overview - Founded in 2006, OrthoPediatrics specializes in pediatric orthopedics, offering over 80 products across major categories including trauma and deformity, scoliosis, and sports medicine [4]. - The company distributes its products in the United States and over 70 countries globally, focusing exclusively on pediatric orthopedic solutions [4].